Recorded fact · drug.trial_access

drug.trial_access for abemaciclib

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact c9465043 resolves to.

The record

Fact id	`c9465043705339e23ce77cc3`
Entity	drug: abemaciclib
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "ABEMACICLIB",
 "recruitingInterventionalCount": 88,
 "notYetRecruitingCount": 16,
 "byPhase": {
  "PHASE4": 2,
  "PHASE1/PHASE2": 22,
  "NA": 7,
  "PHASE1": 10,
  "PHASE3": 8,
  "PHASE2": 37,
  "EARLY_PHASE1": 2
 },
 "trials": [
  {
   "nctId": "NCT06169371",
   "briefTitle": "Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "University of Illinois Chicago",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2023-12-28",
   "conditions": [
    "Breast Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06169371"
  },
  {
   "nctId": "NCT03424005",
   "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2018-03-30",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "France",
    "Germany",
    "Israel",
    "South Korea",
    "Spain",
    "Taiwan",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03424005"
  },
  {
   "nctId": "NCT07214532",
   "briefTitle": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Natera, Inc.",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-05-08",
   "conditions": [
    "Breast Neoplasms",
    "Carcinoma, Ductal, Breast",
    "Receptors, Estrogen (for ER-positive Requirement)"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07214532"
  },
  {
   "nctId": "NCT04633239",
   "briefTitle": "Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2021-07-02",
   "conditions": [
    "Recurrent Ovarian High Grade Serous Adenocarcinoma",
    "Recurrent Platinum-Resistant Ovarian Carcinoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04633239"
  },
  {
   "nctId": "NCT07174336",
   "briefTitle": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Eli Lilly and Company",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2025-12-22",
   "conditions": [
    "Breast Neoplasms",
    "Neoplasm Metastasis"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Belgium",
    "Brazil",
    "Canada",
    "China",
    "France",
    "Germany",
    "Greece"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07174336"
  },
  {
   "nctId": "NCT07521202",
   "briefTitle": "IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Institut fuer Frauengesundheit",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2026-06-19",
   "conditions": [
    "HR+/HER2- Early Breast Cancer"
   ],
   "countries": [
    "Germany"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07521202"
  },
  {
   "nctId": "NCT07114601",
   "briefTitle": "A Study of LY4257496 in Participants With Cancer (OMNIRAY)",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Eli Lilly and Company",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2025-08-06",
   "conditions": [
    "Breast Neoplasms",
    "Colorectal Neoplasms",
    "Prostate Neoplasm"
   ],
   "countries": [
    "United States",
    "Canada",
    "China",
    "France",
    "Germany",
    "Japan",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07114601"
  },
  {
   "nctId": "NCT02523014",
   "briefTitle": "Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Alliance for Clinical Trials in Oncology",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2015-09-28",
   "conditions": [
    "Intracranial Meningioma",
    "Recurrent Meningioma",
    "NF2 Gene Mutation"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT02523014"
  },
  {
   "nctId": "NCT04802759",
   "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2021-06-22",
   "conditions": [
    "Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Israel",
    "South Korea",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04802759"
  },
  {
   "nctId": "NCT07112053",
   "briefTitle": "A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "University of Washington",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2025-11-17",
   "conditions": [
    "Anatomic Stage IV Breast Cancer AJCC v8",
    "Metastatic HER2-Negative Breast Carcinoma",
    "Metastatic Hormone Receptor-Positive Breast Carcinoma"
   ],
   "countries": [
    "United 
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: a9797fd8b19ce14a38e6bdeb6b86a11c0348757a1d52c8a5265eeba2033778bb.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.